paclitaxel + streptozocin + raltitrexed

This drug is a **combination chemotherapy regimen** composed of the agents paclitaxel, streptozocin, and raltitrexed. Each component is a cytotoxic small molecule with distinct mechanisms of action: - **Paclitaxel** is a taxane antineoplastic agent that stabilizes microtubules and inhibits their depolymerization, resulting in mitotic arrest and apoptosis[5]. - **Streptozocin** is a nitrosourea alkylating agent mainly used for pancreatic neuroendocrine tumors; it is selectively toxic to insulin-producing beta cells, causing DNA alkylation and cell death[9]. - **Raltitrexed** is a folate analog antimetabolite that inhibits thymidylate synthase, leading to suppression of DNA synthesis and cellular proliferation[2][4]. Combined, these drugs provide a multi-mechanistic cytotoxic effect targeting tumor cells by impairing DNA synthesis/repair and inducing mitotic arrest. No unique brand or standard regimen for the triple combination is recognized in major clinical guidelines or drug compendia, unlike dual combinations such as paclitaxel plus raltitrexed in solid tumors[1][3].